![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement with Alar, Indivior will secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-1000
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Indivior
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 11, 2023
Details:
The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain severity.
Lead Product(s): Buprenorphine
Therapeutic Area: Psychiatry/Psychology Product Name: ALA-1000
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021